MedTrace Logo

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma

NCT05840289 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2023-05-06

No results posted yet for this study

Summary

Tumour lysis syndrome (TLS) occurs as a consequence of the rapid destruction of malignant cells, spontaneously and/or in response to cytotoxic agents and immunotherapies. TLS is a feature of highly proliferative diseases with heavy tumor burden, such as high-grade non-Hodgkin lymphomas (NHL, typically Burkitt's lymphoma). We evaluated fractionating first rituximab dose to prevent TLS in a real-life B-cell NHL cohort of patients treated at University Hospital of Geneva between 2010 and 2020.

Conditions

  • Aggressive B-Cell Non-Hodgkin Lymphoma

Interventions

OTHER

fractionated first dose rituximab

Patients at high-risk to develop tumor lysis syndrome received a initial fractionated dose of rituximab over 2 or 3 days

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Noemie Lang, MD · University Hospital, Geneva

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-24
Primary Completion
2023-05-01
Completion
2023-05-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05840289 on ClinicalTrials.gov